Jim Simons Kazia Therapeutics LTD Call Options Transaction History
Renaissance Technologies LLC
- $63.6 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KZIA
# of Institutions
12Shares Held
323KCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY198KShares$45,5050.0% of portfolio
-
Hsbc Holdings PLC London, X064KShares$14,7090.0% of portfolio
-
Xtx Topco LTD London, X018.5KShares$4,2520.0% of portfolio
-
Two Sigma Securities, LLC New York, NY18.4KShares$4,2370.0% of portfolio
-
Rhumbline Advisers Boston, MA12.2KShares$2,7990.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $3.48M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...